Speaker illustration

Mr Michael Boettcher

Bayer AG, Wuppertal (Germany)

Vericiguat: A QTc interval study in patients with coronary artery disease

Event: ESC Congress 2021 - The Digital Experience

Topic: Pharmacotherapy

Session: Chronic heart failure e-posters

Thumbnail

This platform is supported by

logo Novo Nordisk